<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096304</url>
  </required_header>
  <id_info>
    <org_study_id>MUSC-100781</org_study_id>
    <secondary_id>CDR0000378045</secondary_id>
    <secondary_id>MUSC-HR-11325</secondary_id>
    <secondary_id>AVENTIS-MUSC-100781</secondary_id>
    <nct_id>NCT00096304</nct_id>
  </id_info>
  <brief_title>Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer</brief_title>
  <official_title>Phase I Trial of Epirubicin and Taxotere in Patients With Metastatic Androgen Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Combining more than one&#xD;
      drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when&#xD;
      given with docetaxel in treating patients with metastatic prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual&#xD;
  </why_stopped>
  <start_date type="Actual">June 8, 2004</start_date>
  <completion_date type="Actual">November 30, 2007</completion_date>
  <primary_completion_date type="Actual">September 6, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Measurable disease with any prostate-specific antigen (PSA) value&#xD;
&#xD;
                    -  Unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥&#xD;
                       10 mm by spiral CT scan&#xD;
&#xD;
                    -  Histologic confirmation required if measurable disease is confined to a&#xD;
                       solitary lesion&#xD;
&#xD;
               -  Non-measurable disease with PSA ≥ 5 ng/mL*&#xD;
&#xD;
                    -  The following are considered non-measurable disease:&#xD;
&#xD;
                         -  Bone lesions&#xD;
&#xD;
                         -  Pleural or pericardial effusion&#xD;
&#xD;
                         -  Ascites&#xD;
&#xD;
                         -  CNS lesions&#xD;
&#xD;
                         -  Leptomeningeal disease&#xD;
&#xD;
                         -  Irradiated lesions unless disease progression was documented after&#xD;
                            prior radiotherapy NOTE: *Patients with PSA ≥ 5 ng/mL only are not&#xD;
                            eligible&#xD;
&#xD;
          -  Progressive systemic disease despite ≥ 1 prior standard endocrine therapy with&#xD;
             orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonist, or&#xD;
             diethylstilbestrol, as indicated by 1 of the following criteria:&#xD;
&#xD;
               -  Objective evidence of increase &gt; 20% in the sum of the longest diameters of&#xD;
                  target lesions from the time of maximal regression OR the appearance of 1 or more&#xD;
                  new lesions&#xD;
&#xD;
               -  One or more new lesions on bone scan secondary to prostate cancer AND PSA ≥ 5&#xD;
                  ng/mL&#xD;
&#xD;
               -  Elevated PSA (≥ 5 ng/mL) with 2 consecutive increases from baseline (taken ≥ 1&#xD;
                  week apart)&#xD;
&#xD;
          -  Serum testosterone ≤ 50 ng/dL for patients without bilateral orchiectomy&#xD;
&#xD;
               -  Patients who have not had a bilateral orchiectomy should continue therapy with&#xD;
                  primary testicular androgen suppression (e.g., LHRH analogues)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  AST or ALT normal AND alkaline phosphatase ≤ 5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  AST or ALT ≤ 1.5 times ULN AND alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
               -  AST or ALT ≤ 5 times ULN AND alkaline phosphatase normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled high blood pressure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No serious uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 3 months&#xD;
             after study participation&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No prior severe hypersensitivity reaction to docetaxel or other drug formulated with&#xD;
             polysorbate 80&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy, including estramustine or suramin for prostate cancer&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior antiandrogen therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy except steroids for adrenal insufficiency, hormones for&#xD;
             non-disease-related conditions (e.g., insulin for diabetes), or intermittent&#xD;
             dexamethasone as an antiemetic&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 8 weeks since prior strontium chloride Sr 89 or samarium Sm 153 lexidronam&#xD;
             pentasodium&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior surgery and recovered&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew S. Kraft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Leone</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina, Hollings Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

